A phase II trial of gefitinib and concurrent radiation therapy for locally advanced non-small cell lung cancer patients harboring sensitive EGFR mutations.
Latest Information Update: 16 May 2011
Price :
$35 *
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 16 May 2011 New trial record